HCPCS Code J7330: Autologous Cultured Chondrocytes, Implant

Read about HCPCS code J7330 for autologous cultured chondrocytes, implant. Learn billing, documentation, and coverage rules for cartilage repair procedures.

Use Code

## **What are autologous cultured chondrocytes?** HCPCS code J7330 is defined as “Autologous cultured chondrocytes, implant.” This code is used to report the supply of cartilage cells harvested from an eligible patient’s healthy cartilage, cultured in a laboratory, and then implanted to repair full-thickness cartilage defects in the knee joint. The therapy, known as autologous chondrocyte implantation (ACI), is often recommended for patients with cartilage damage resulting from acute or repetitive trauma, and is intended to restore the articular surface, improve joint alignment, and support long-term cartilage repair. J7330 is used to bill for the chondrocyte product itself, not the surgical procedure. Surgical implantation is billed separately using CPT codes, such as 27412 (Autologous chondrocyte implantation, knee, open). The procedure often uses a porcine collagen membrane to hold the cultured cells in place within the defect. Following implantation, patients typically undergo a structured physical therapy program to promote healing, restore range of motion, and achieve improved joint function. Because this is a highly specialized therapy, healthcare professionals must carefully document patient selection, defect size, and treatment planning to optimize clinical outcomes and meet payer coverage requirements.

## **Documentation requirements for HCPCS code J7330** Payers require complete records demonstrating that the patient meets all clinical selection guidelines, that the chondrocytes were properly harvested and cultured. That implantation was performed in accordance with accepted medical standards. The following elements should be present in the medical record: ### **Diagnosis and medical necessity** Include an ICD-10 diagnosis code confirming a focal articular cartilage defect (e.g., M23.2 – Derangement of meniscus, M24.1 – Articular cartilage disorder). Document that conservative treatment or prior procedures (e.g., debridement, microfracture) have failed. ### **Patient selection criteria** Records should confirm that the patient meets clinical criteria for ACI: - Full-thickness (Grade III or IV) defect of 2–10 cm² - Appropriate age and activity level for cartilage restoration - No generalized osteoarthritis or inflammatory arthritis - Joint stability and alignment sufficient to support graft success ### **Procedure documentation** Include the date and details of the chondrocyte harvest procedure, lab culture process, and final number of cells prepared for implantation. Attach the operative note from the implantation procedure. ### **Orders and supporting records** Maintain a signed physician order authorizing implantation, along with MRI or arthroscopy images confirming defect size and location. Document the treatment plan, post-op rehab protocol, and follow-up visits.

## **Billing requirements of HCPCS code J7330** Accurate billing for HCPCS code J7330 is crucial due to the high cost of autologous cultured chondrocyte products and the stringent payer requirements for coverage. ### **Billing for implant vs. procedure** Use HCPCS J7330 to bill for the implant material itself, while the related surgical implantation procedure must be billed separately using CPT code 27412. Both codes can be submitted on the same claim to reflect the product and procedure. ### **Prior authorization** Prior authorization or payer approval is typically required before performing ACI and billing for J7330. Ensure all medical necessity documentation is complete and authorization is obtained before scheduling the procedure. ### **Claim submission** Claims must be submitted on the correct form, using the CMS-1500 for professional claims or the CMS-1450 (UB-04) for facility billing. On the CMS-1500, report J7330 in Item 24D for the implant and CPT 27412 in Item 24D for the surgical implantation procedure. Be sure to clearly document and state the quantity of the implant used, ensuring it aligns with manufacturer specifications and the operative note in the medical record. ### **Revenue codes and facility billing** Facilities should confirm the appropriate revenue code for J7330, commonly 0278 (Medical/Surgical Supplies & Devices, Other Implants) or 0636 (Drugs Requiring Detailed Coding), depending on payer requirements. ### **Specialty pharmacy considerations** If a specialty pharmacy supplies the implant, that pharmacy is responsible for submitting the claim for J7330. In this case, the facility should only bill for the implantation procedure (CPT 27412).

## **Applicable modifiers for HCPCS code J7330** When billing for J7330, use the following modifiers as appropriate to ensure accurate claim submission and compliance with payer requirements: - **JW modifier**: Report any discarded amounts of unused chondrocyte product, ensuring the wastage matches what is documented in the operative note and product log. - **KX modifier**: Append to confirm that all medical necessity and payer coverage criteria (e.g., appropriate defect size, failed conservative treatment) have been met. - **GA modifier**: Use if an Advance Beneficiary Notice (ABN) was obtained for a service expected to be denied by Medicare. - **GY modifier**: Indicate that the service is statutorily excluded from Medicare coverage when billing only to receive a denial for secondary payer processing.

## **Other relevant codes** - **J7331**: Hyaluronan or derivative, synojoynt, for intra-articular injection, 1 mg - **J7332**: Hyaluronan or derivative, triluron, for intra-articular injection, 1 mg

Frequently asked questions

Yes. Use J7330 to bill for the implant product, and CPT 27412 for the surgical implantation procedure. If a specialty pharmacy delivers the implant, only CPT 27412 is billed by the facility, and J7330 is billed separately by the pharmacy.

Documentation should include lesion details (location, size, nature), prior failed conservative treatments, details of arthroscopy or cartilage harvest, and clinical rationale for ACI over other options.

Yes. Policies vary—some payers require prior authorization with detailed clinical documentation. Providers should reference payer-specific medical necessity criteria and revenue code requirements to ensure compliance.